PAVM
PAVmed Inc.
$7.16
+0.28%
2026-05-08
About PAVmed Inc.
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Key Fundamentals
Forward P/E
-2.60
EPS (TTM)
$-5.63
ROE
-32.3%
Revenue Growth (YoY)
420.0%
Profit Margin
564.8%
Debt/Equity
59.86
Price/Book
0.71
Beta
0.64
Market Cap
$51.8M
Avg Volume (10D)
16K
Recent Breakout Signals
No recent breakout signals detected for PAVM.
Recent Price Range (60 Days)
60D High
$10.98
60D Low
$6.95
Avg Volume
24K
Latest Close
$7.16
Get breakout alerts for PAVM
Sign up for Breakout Scanner to receive daily notifications when PAVM triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
PAVmed Inc. (PAVM) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PAVM daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PAVM operates in the Healthcare sector within the Medical Devices industry. Data is provided for informational purposes only and does not constitute financial advice.